[HTML][HTML] A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin

DG Alleva, PD Crowe, L Jin, WW Kwok… - The Journal of …, 2001 - Am Soc Clin Investig
DG Alleva, PD Crowe, L Jin, WW Kwok, N Ling, M Gottschalk, PJ Conlon, PA Gottlieb
The Journal of clinical investigation, 2001Am Soc Clin Investig
The 9–23 amino acid region of the insulin B chain (B (9-23)) is a dominant epitope
recognized by pathogenic T lymphocytes in nonobese diabetic mice, the animal model for
type 1 diabetes. We describe herein similar B (9-23)-specific T-cell responses in peripheral
lymphocytes obtained from patients with recent-onset type 1 diabetes and from prediabetic
subjects at high risk for disease. Short-term T-cell lines generated from patient peripheral
lymphocytes showed significant proliferative responses to B (9-23), whereas lymphocytes …
The 9–23 amino acid region of the insulin B chain (B(9-23)) is a dominant epitope recognized by pathogenic T lymphocytes in nonobese diabetic mice, the animal model for type 1 diabetes. We describe herein similar B(9-23)-specific T-cell responses in peripheral lymphocytes obtained from patients with recent-onset type 1 diabetes and from prediabetic subjects at high risk for disease. Short-term T-cell lines generated from patient peripheral lymphocytes showed significant proliferative responses to B(9-23), whereas lymphocytes isolated from HLA and/or age-matched nondiabetic normal controls were unresponsive. Antibody-mediated blockade demonstrated that the response was HLA class II restricted. Use of the highly sensitive cytokine-detection ELISPOT assay revealed that these B(9-23)-specific cells were present in freshly isolated lymphocytes from only the type 1 diabetics and prediabetics and produced the proinflammatory cytokine IFN-γ. This study is, to our knowledge, the first demonstration of a cellular response to the B(9-23) insulin epitope in human type 1 diabetes and suggests that the mouse and human diseases have strikingly similar autoantigenic targets, a feature that should facilitate development of antigen-based therapeutics.
The Journal of Clinical Investigation